Communiqués Guardant Health, Inc.

Actions

GH

US40131M1099

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
27,1 ^USD	-1,35 %		+6,19 %	+0,18 %

24/05	Mise à jour sectorielle : Les actions du secteur de la santé sont plus douces dans les échanges de l'après-midi de vendredi	MT
24/05	Les actions de Guardant Health augmentent alors que le test de détection du cancer colorectal reçoit la recommandation du groupe d'experts de la FDA	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Guardant Health Named to TIME100 Most Influential Companies	31/05	BU
Guardant Health : 2024 ESG Report	31/05	PU
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening	30/05	BU
Panel recommends blood test to detect colon cancer for FDA approval	24/05	AQ
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option	24/05	BU
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening	23/05	BU
Guardant Health to Participate in Upcoming Investor Conferences	22/05	BU
Guardant Health reçoit la certification IVDR de l’UE pour la biopsie liquide Guardant360® CDx destinée au profilage des mutations tumorales dans tous les cancers solides et les indications de diagnostic compagnon	21/05	BU
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications	21/05	BU
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	20/05	AQ
Guardant Health to present real-world data supporting performance of Shield blood test for colorectal cancer screening at 2024 Digestive Disease Week	17/05	AQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	17/05	BU
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week	16/05	BU
Guardant Health : Q1 2024 Earnings Call - Presentation	09/05	PU
Guardant Health: Q1 Earnings Snapshot	09/05	AQ
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance	09/05	BU
Guardant Health to Participate in Upcoming Investor Conferences	07/05	BU
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone	07/05	BU
FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23	23/04	AQ
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	22/04	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Guardant Health, Inc.

Actions

GH

US40131M1099

Communiqués

Filtres